Study at a glance
How do vitamin D receptors affect heart muscle in mice?
Two mouse studies examined what happens when heart muscle cells lose the vitamin D receptor, the protein that receives vitamin D signals. They used different genetic designs and different types of heart stress. Removing a receptor is different from having a low vitamin D blood level or taking a supplement.
What happened to mouse hearts in the 2011 study?
In the 2011 experiment, mice without working receptors in heart muscle had larger muscle cells and thicker heart walls. The measured pumping function did not show a significant decline, and extra scar tissue was not found. Measured blood pressure was not higher. A separate experiment in newborn rat heart cells suggested a possible link with a cell-growth signalling pathway, but did not prove that this pathway explained all the changes.
How did mouse hearts respond to stress in the 2024 study?
The 2024 study found no abnormal heart pattern before stress in its measured comparisons. After surgery increased the pressure against which the heart pumped, mice lacking the receptor had worse results on some ultrasound measures of pumping. They did not have clearly greater muscle-cell enlargement or measured scarring. Other measurements of contraction and relaxation did not show the same difference. An exploratory analysis of gene activity used only one heart section per group, so its findings need further testing.
Do these mouse studies show a heart benefit from vitamin D supplements?
The results suggest that vitamin D receptor signals can affect the heart’s response in these mouse models. They do not show that receptor loss always causes the same structural or functional changes. The experiments were small, and their different designs may help explain the different results without proving why they differed. Neither study establishes that vitamin D supplements prevent or reverse changes in human hearts, or provides a blood target or dose.
Read the full article below ↓Does vitamin D receptor (VDR) signalling within heart muscle affect how the heart remodels? A 2011 mouse experiment by Chen and colleagues found enlargement after receptor deletion, while a later experiment produced a different pattern of enlargement and impaired function. Together, these studies make a useful distinction between a receptor’s role in a particular model and the effects of vitamin D supplements in people. Here, remodelling means a change in the heart’s structure or cellular programme. For the shorter account, read Vitamin D Receptors in Heart Muscle and Cardiac Remodelling: Study Summary.
The question: a local heart-cell effect or a whole-body effect?
The heart physiology overview describes several interacting cardiovascular compartments. This study concerns cardiomyocytes, the muscle cells that generate the heart’s contraction. It asks what changes when those cells lose functional vitamin D receptors. It does not study the occurrence of heart attacks, compare supplements in patients or establish a blood vitamin D target.
The distinction is important because a whole-animal receptor knockout changes many organs simultaneously. An enlarged heart in that setting might reflect changes inside heart cells, altered pressure against which the heart pumps, disturbed mineral regulation or a combination. A tissue-selective experiment narrows the question by changing the receptor in one cell population. Background on vitamin D receptors explains why removing a receptor is different from changing the supply of the hormone that binds it.
Hypertrophy means enlargement of existing muscle cells. It is not synonymous with fibrosis, the accumulation of connective tissue, or with impaired pumping. A useful appraisal therefore follows each measurement separately: cell size, ventricular mass, wall thickness, chamber volume, gene expression and functional measurements. Calling every change ‘heart damage’ would lose the distinctions the experiments were designed to examine.
How the 2011 experiment was constructed
Chen and colleagues used Cre-Lox genetic engineering to remove exon 4 of the VDR gene in cardiomyocytes. The mice were approximately six months old and maintained on a C57BL/6J background. The principal comparison used MLC-Cre/VDR floxed/null mice and VDR floxed/null controls. One receptor allele was already inactive throughout the body; Cre removed the remaining targeted allele in the heart muscle cells. Thus, the control was not simply an untreated, fully wild-type mouse.
This architecture has two implications. First, comparing animals that share the floxed/null background helps isolate the additional cardiomyocyte deletion. Second, a result on that background cannot automatically be assumed to be identical in an animal with two functioning receptor alleles in every other tissue. Other control genotypes, including Cre-only and floxed animals, helped assess whether parts of the genetic construction themselves changed the phenotype.
Deletion was checked using isolated and sorted cardiomyocytes, rather than relying only on a whole-heart sample. This matters because heart tissue also contains fibroblasts, endothelial cells and other populations. Receptor RNA remaining in a whole-heart preparation can originate from cells that were never intended to undergo deletion. Conversely, a reduced whole-heart RNA signal does not by itself reveal exactly which cells have lost their receptor.
The investigators examined baseline animals and animals receiving isoproterenol, a drug used to provoke cardiac growth through adrenergic stimulation. Subcutaneous pumps delivered 15 mg/kg/day for seven days; control pumps contained buffer. This was an experimental cardiac stress protocol, not a vitamin D treatment regimen. Plasma calcium and parathyroid hormone did not show the major abnormalities associated with the global knockout.
Those mineral measurements help address a specific alternative explanation. They do not demonstrate that every systemic influence was identical. The wider role of vitamin D in calcium physiology remains relevant because circulating calcium balance and signalling within a muscle cell are related but distinct levels of regulation.
What changed in ventricular mass
The main results table reported the following left ventricular weight divided by body weight. This ratio describes ventricular mass relative to animal size, not a person’s risk of cardiovascular disease. Values are group means with standard deviations; the table reports 8-12 mice per group.
| Experimental group | Left ventricular weight/body weight, mg/g |
|---|---|
| Control, without isoproterenol | 2.69 ± 0.21 |
| Cardiomyocyte receptor deletion, without isoproterenol | 3.16 ± 0.27 |
| Control, with isoproterenol | 3.27 ± 0.20 |
| Cardiomyocyte receptor deletion, with isoproterenol | 3.78 ± 0.37 |
The baseline genotype contrast was statistically significant at P<0.01; the comparison between the two isoproterenol-exposed groups was significant at P<0.05. These results support a larger ventricular mass in the deletion model under both conditions. Standard deviations describe dispersion among the observations, however, and should not be read as confidence intervals for the between-group effect.
Microscopy also showed larger cardiomyocytes, and echocardiography showed thicker ventricular walls. These observations provide complementary evidence: increased mass alone could have several explanations, whereas larger individual cells support a hypertrophic component. The histological method measured 400 cells per heart in 4-5 hearts per genotype. Those hundreds of cells do not become hundreds of independent animals; biological replication remains at the heart or animal level.
Larger muscle did not mean demonstrated pump failure
The 2011 report did not find increased interstitial fibrosis, and reported no significant genotype difference in the assessed systolic or diastolic function. Its supplementary table gives baseline ejection fractions of 50.14% in controls and 50.59% in the cardiomyocyte-deletion group. The chamber volumes were smaller in the deletion model. Ejection fraction is the proportion of the filled ventricular volume expelled during a beat, so it can remain similar even when absolute volumes differ.
This is a particularly important reading boundary. Similar ejection fractions do not establish that every feature of cardiac performance is identical, and a nonsignificant comparison does not prove equivalence. Equally, structural enlargement cannot be rewritten as a measured decline in pumping when the functional tests did not demonstrate that decline. The paper identifies remodelling within the duration and sensitivity of its measurements.
Tail-cuff measurements found lower diastolic and mean arterial pressure in the cardiomyocyte-deletion mice; the lower systolic-pressure estimate was not statistically significant. That finding argues against elevated measured blood pressure as the straightforward explanation for the enlargement. It also shows why heart-cell growth and vascular tone should not be collapsed into one endpoint. The study did not directly measure every influence on cardiac loading.
The proposed signalling route
The investigators found increased expression of modulatory calcineurin inhibitory protein 1 (MCIP1), also called RCAN1, and of growth-associated genes including atrial natriuretic peptide and alpha skeletal actin. MCIP1 is connected with calcineurin/NFAT signalling: calcineurin is an enzyme involved in cellular signalling, and NFAT denotes a family of proteins that can regulate gene transcription. The paper proposed that this pathway helps connect receptor loss with hypertrophic growth.
A complementary experiment used ventricular cells from newborn rats. The supplementary methods describe 48 hours of exposure to active vitamin D, with isoproterenol at 1 micromole/litre during the final 24 hours. Active vitamin D partially reduced the isoproterenol-associated increases in MCIP1 RNA, protein and promoter activity. The assays had 3-5 observations per group. This was a separate cell-culture experiment, not treatment of the adult knockout mice.
The convergence is informative, but it leaves a mechanistic gap. Increased MCIP1 in the enlarged hearts and partial suppression in cultured cells make the pathway a plausible contributor. They do not by themselves show that blocking this pathway would abolish the whole phenotype, or that it is the only route involved. A targeted rescue or pathway-interruption experiment would answer a stronger mediation question. The cell experiment also changes species, developmental stage and experimental environment relative to the adult mouse heart.
What the later mouse experiment adds
Zupcic and colleagues revisited cardiomyocyte VDR deletion in 2024. Male mice underwent sham surgery or transverse aortic constriction at four months of age and were studied four weeks later. Constriction narrows the aorta and increases the load against which the heart pumps. Unlike the earlier floxed/null construction, this model used two floxed receptor alleles, targeting exon 3, without the same global heterozygous VDR-deficient background.
The later study found no abnormal baseline cardiac phenotype in its measured comparisons. Pressure overload produced hypertrophy in both genotypes, with similar cardiomyocyte enlargement and histologically measured fibrosis. However, the receptor-deletion animals had lower echocardiographic ejection fraction and fractional shortening after constriction. Fractional shortening describes the change in ventricular internal diameter during contraction. Each of the two constriction groups had five mice in these echocardiographic comparisons.
The functional picture was not uniformly different across methods. Catheter-derived indices of contraction and relaxation did not show a corresponding genotype difference, and the between-genotype chamber-diameter differences were not statistically significant. The paper therefore supports a difference in specified ultrasound measures under pressure overload, rather than a claim that every measure of function deteriorated more.
The authors also used spatial transcriptomics, which maps RNA patterns within tissue sections. The inner, more stressed regions showed stronger inflammation-related and fibrosis-related regulatory patterns in the knockout section. However, only one heart section per genotype entered this spatial comparison. Thousands of measured tissue spots cannot replace independent hearts, and the regulatory networks were computationally inferred. These results identify hypotheses rather than establish a replicated causal chain.
There was also a useful mismatch between molecular and tissue findings: increased collagen-related transcription was not accompanied by a demonstrated increase in histological fibrosis at the four-week endpoint. A signal associated with fibrosis is not the same observation as additional deposited scar tissue.
Why the two studies should not be flattened into one answer
The studies differ in the genetic background of receptor deletion, age, stressor and observation period. Seven days of pharmacological stimulation and four weeks of surgically imposed pressure overload are different biological challenges. The 2024 authors proposed that global receptor haploinsufficiency in the earlier model could help explain the different phenotype. That is a plausible interpretation, not a directly tested explanation of the disagreement.
Their findings consequently support a narrower proposition than ‘receptor loss always enlarges the heart’. Receptor signalling can influence how cardiac cells respond in these experimental settings, but the manifestation depends on the model and endpoint. This is an application of matching the evidence design to the question: a genetic experiment is powerful for a receptor-dependent mechanism while remaining indirect evidence about a nutritional intervention.
Nor does the later study simply erase the earlier one. The appropriate response is to retain the original findings, identify the conditions under which they were observed and show the reader where another model agrees or differs. A direct comparison using matched genetics, the same stress protocol and consistent functional measurements would more clearly separate the competing explanations.
Strengths, limitations and what remains unanswered
The 2011 study combined genetic verification, tissue measurements, ultrasound, blood measurements and cell experiments. Blinded assessment was reported for echocardiographic images and myocyte size. These features reduce dependence on a single assay. Nevertheless, sample sizes were small and varied across outcomes, and the report does not supply a complete animal-flow account or clearly describe treatment-allocation randomisation. Sex-specific inference is also limited by the absence of a clearly reported sex breakdown in the principal methods.
The later experiment adds a different stress model and further control genotypes, with blinded histological assessment. It remains a small study in male mice, and its exploratory spatial analysis has particularly limited biological replication. Neither study establishes what happens after decades of human exposure, in women and men with different diseases, or after correcting a measured vitamin D deficiency.
Genetic deletion also cannot be translated into a numerical blood vitamin D threshold. A receptor can be absent despite ample hormone supply; conversely, a lower circulating measurement does not establish complete receptor loss. The distinction between vitamin D status and biological effect is central here. These papers do not provide a dose-response curve for supplementation or a target concentration for preventing remodelling.
A further step would be needed to connect this biology with clinical benefit: studies of a defined intervention in a defined human population, measuring the relevant structural, functional or clinical outcome. Correlation and causation remain separate issues even when a plausible mechanism exists. A mechanism can help explain a trial finding, but cannot supply a missing trial result.
What this evidence establishes
The 2011 experiment supports a role for cardiomyocyte VDR in restraining hypertrophic remodelling in its particular mouse model, without a demonstrated loss of the assessed pumping function. The 2024 experiment points instead to impaired ultrasound measures under pressure overload without clearly greater cell enlargement or measured fibrosis. Read together, they show why receptor biology, heart structure and heart function need separate descriptions. They justify further mechanistic investigation; they do not establish that vitamin D supplements prevent or reverse cardiac remodelling in people.
Scientific sources
Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy. Circulation. 2011;124(17):1838-1847. DOI: 10.1161/CIRCULATIONAHA.111.032680. PMID: 21947295. The principal experiment; supplementary methods and echocardiography are part of this publication.
Zupcic A, Latic N, Oubounyt M, Ramesova A, Carmeliet G, Baumbach J, Elkjaer ML, Erben RG. Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice. International Journal of Molecular Sciences. 2024;25(11):5929. DOI: 10.3390/ijms25115929. PMID: 38892126. A separate mouse experiment used here to assess the consistency and limits of the earlier findings.
Related reading
A cross-sectional study on vitamin D deficiency and cardiac electrophysiology: Evaluating the frontal QRS-T angle
This study aimed to assess the influence of vitamin D deficiency on the frontal QRS-T (f[QRS-T]) angle on electrocardiograms, a potential marker of arrhythmic risk and cardiac mortality, to address a notable gap in the current understanding.
Original paper ↗Read more →Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice
This study aimed to further elucidate the role of vitamin D signaling in the development of left ventricular (LV) hypertrophy and dysfunction.
Original paper ↗Read more →Association between Vitamin D and Heart Failure Mortality in 10,974 Hospitalized Individuals
We sought to evaluate the outcomes of patients with vitamin D supplementation, compared with a matched cohort using real-world big data of HF hospitalization.
Original paper ↗Read more →Correlation between Sirtuin 1 downregulation and reduced vitamin D receptor expression in patients with diabetic neuropathy
Fifty-one participants with T2D, who underwent neurological assessment for DN were recruited.
Original paper ↗Read more →Current Knowledge of the Impact of Vitamin D in Coronary Artery Disease
This review will discuss randomized controlled trials conducted from 2020 forward, aiming to elucidate whether vitamin D supplements have the potential to be used as an add-on treatment for coronary artery disease.
Original paper ↗Read more →Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic Review
We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate the effect of VDRAs on kidney function and adverse events.
Original paper ↗Read more →Effects of vitamin D supplementation on inflammatory markers in heart failure: a systematic review and meta-analysis of randomized controlled trials
In meta-analyses, vitamin D-supplemented groups had lower concentrations of tumor necrosis factor-alpha (TNF-α) at follow-up compared with controls (n = 380; p = 0.04).
Original paper ↗Read more →Genome-wide association study of vitamin D concentrations and bone mineral density in the African American-Diabetes Heart Study
To identify genetic factors contributing to vitamin D and BMD measures, association analysis of >14M variants was conducted in a maximum of 697 African American-Diabetes Heart Study participants with type 2 diabetes (T2D).
Original paper ↗Read more →Impact of Vitamin D Supplementation on Bone Mineral Density and All-Cause Mortality in Heart Transplant Patients
However, the efficacy of VD supplementation on bone mineral density (BMD) and its association with all-cause mortality is underinvestigated.
Original paper ↗Read more →Interactions between vitamin D receptor (VDR) gene and Interleukin-6 gene and environment factors on coronary heart disease risk in a Chinese Han population
Stratified analysis for gene: smoking interaction was investigated by logistic regression.
Original paper ↗Read more →Lack of vitamin D signalling per se does not aggravate cardiac functional impairment induced by myocardial infarction in mice
Epidemiological studies have linked vitamin D deficiency to an increased incidence of myocardial infarction and support a role for vitamin D signalling in the pathophysiology of myocardial infarction.
Original paper ↗Read more →Low skeletal muscle density is independently associated with cardiac valve calcification in dialysis patients
This study evaluated how muscle mass and muscle quality relate to the risk of CVC in dialysis patients.
Original paper ↗Read more →Muscle or Heart? Functional Impact of Sarcopenia and Heart Failure in Geriatric Inpatients
To evaluate the individual and combined impact of sarcopenia (SARC) and heart failure (HF) on functional performance, systemic biomarkers, and structural cardiac changes in hospitalized older adults.
Original paper ↗Read more →Perturbations in cardiac metabolism in a human model of acute myocardial ischaemia
Acute myocardial ischaemia and the transition from reversible to irreversible myocardial injury are associated with abnormal metabolic patterns.
Original paper ↗Read more →Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
We aimed to define the prevalence of sepsis death in people with CHF and to ascertain its risk marker profile.
Original paper ↗Read more →Prevention of post-cardiac surgery vitamin D deficiency in children with congenital heart disease: a pilot feasibility dose evaluation randomized controlled trial
We conducted a two-arm, double-blind dose evaluation randomized controlled trial in children requiring cardiopulmonary bypass for congenital heart disease.
Original paper ↗Read more →The Relationship Between Preoperative Serum Ionized Calcium, Vitamin D, and Postoperative Bleeding After Major Cardiac Surgery
The role of calcium in coagulation homeostasis is well established, although the relationship between calcium levels and postoperative bleeding in major cardiac surgery remains largely unexplored.
Original paper ↗Read more →The relationship between serum 25-hydroxyvitamin D levels and dyslipidemia risk: insights from a study of elderly Chinese diabetic foot ulcer patients
This study systematically evaluated the association between serum 25-hydroxyvitamin D [25(OH)D] levels and dyslipidemia in elderly DFU patients, and explored potential non-linear dose-response patterns and interaction effects.
Original paper ↗Read more →The Relationship Between Vitamin D Levels and Cardiac Remodelling in a Pediatric Dilated Cardiomyopathy Population: A Case-Control Study
Dilated cardiomyopathy (DCM) is a significant contributor to heart failure (HF) in the pediatric population despite its lower incidence compared to adults.
Original paper ↗Read more →The role of vitamin D in skeletal and cardiac muscle function
Myopathy is a feature of many inflammatory syndromes.
Original paper ↗Read more →The role of vitamin D receptor and IL‐6 in COVID‐19
This study investigated the changes in vitamin D receptor (VDR) expression and interleukin 6 levels in patients with COVID‐19.
Original paper ↗Read more →Original sources
Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy
Published in Circulation (2011).
Publication details
Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG. Cardiomyocyte-Specific Deletion of the Vitamin D Receptor Gene Results in Cardiac Hypertrophy. Circulation. 2011;124(17):1838-1847. DOI: 10.1161/CIRCULATIONAHA.111.032680. PMID: 21947295. The principal experiment; supplementary methods and echocardiography are part of this publication.
Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice
This study aimed to further elucidate the role of vitamin D signaling in the development of left ventricular (LV) hypertrophy and dysfunction.
Publication details
Zupcic A, Latic N, Oubounyt M, Ramesova A, Carmeliet G, Baumbach J, Elkjaer ML, Erben RG. Ablation of Vitamin D Signaling in Cardiomyocytes Leads to Functional Impairment and Stimulation of Pro-Inflammatory and Pro-Fibrotic Gene Regulatory Networks in a Left Ventricular Hypertrophy Model in Mice. International Journal of Molecular Sciences. 2024;25(11):5929. DOI: 10.3390/ijms25115929. PMID: 38892126. A separate mouse experiment used here to assess the consistency and limits of the earlier findings.